A Phase I and Pharmacokinetic Study of Oral Dabrafenib in Children and Adolescent Patients with Recurrent or Refractory BRAF V600 Mutation-Positive Solid Tumors.
Mark W KieranBirgit GeoergerIra J DunkelAlberto BroniscerDarren R HargravePooja HingoraniIsabelle AertsAnne-Isabelle BertozziKenneth J CohenTrent R HummelViolet ShenEric BouffetChristine A PratilasAndrew D J PearsonLillian TsengNoelia NebotSteven GreenMark W RussoJames A WhitlockPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)
In this first clinical trial in pediatric patients with pretreated BRAF V600-mutant tumors, dabrafenib was well tolerated while achieving target exposure levels; the average treatment duration was >1 year with many patients still on treatment. The phase II component is also closed and will be reported separately.